Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ivan Rykov"'
Autor:
Ilya Tsimafeyeu, Galina Statsenko, Liubov Vladimirova, Natalia Besova, Grigory Raskin, Ivan Rykov, Anastasia Mochalova, Igor Utyashev, Svetlana Gorbacheva, Vasily Kazey, Evgenia Gavrilova, Nadezhda Dragun, Vladimir Moiseyenko, Sergei Tjulandin, Elena Artamonova
Publikováno v:
Investigational New Drugs. 41:324-332
Purpose Alofanib is a small-molecule allosteric extracellular FGFR2 inhibitor. We report safety and preliminary efficacy from the first-in-human phase 1b study of alofanib in heavily pretreated patients with advanced gastric cancer. Methods The stand
Autor:
Ivan Rykov
Publikováno v:
Russian Journal of Management. 10:76-80
The article examines the key aspects of the problem of non-payments in the domestic electric power industry, shows the impact of non-payments on the general state and level of economic security of economic entities engaged in the generation, transpor
Autor:
Ivan Rykov
Publikováno v:
Russian Journal of Management. 9:106-110
The article considers the existing views on the definition, elements of economic security of an enterprise, as well as typification features used in solving problems of classification of factors threatening it. The author systematizes traditional app
Autor:
Grigory Raskin, Vasily Kazey, Svetlana Gorbacheva, Aiyyna Nikiforova, Galina Statsenko, Elena Artamonova, Liubov Vladimirova, Natalia Besova, Anastasia Mochalova, Ivan Rykov, Vladimir Moiseyenko, Igor Utyashev, Sergei Iugai, Nadezhda Dragun, Dmitry Reznikov, Evgenia Gavrilova, Sergei Tjulandin, Ilya Tsimafeyeu
Publikováno v:
Cancer Research. 82:3481-3481
Alofanib is a potent, small molecule, allosteric inhibitor that binds to the non-active extracellular site of IIIc and IIIb FGFR2 isoforms. Phase 1b clinical study (RPT835GC1B) met its primary endpoints and recommended phase 2 dose was described earl
Autor:
Ilya Tsimafeyeu, Liubov Yu Vladimirova, Anastasia Mochalova, Natalia Besova, Galina Statsenko, Ivan Rykov, Igor A. Utyashev, Grigory Raskin, Vasily Kazey, Elena Artamonova, Vladimir Moiseyenko, Sergei Tjulandin
Publikováno v:
Journal of Clinical Oncology. 40:e16077-e16077
e16077 Background: Alofanib (RPT835) is a first-in-class allosteric inhibitor that induces conformational changes in the extracellular domain of FGFR2. Here, we present the final results of the phase Ib clinical study (RPT835GC1B) of alofanib. Method
Autor:
Sergei Tjulandin, Galina Statsenko, Elena Artamonova, Liubov Yu Vladimirova, Natalia Besova, Anastasia Mochalova, Ivan Rykov, Vladimir Moiseyenko, Igor A. Utyashev, Sergei Iugai, Vasily Kazey, Grigory Raskin, Nadezhda Dragun, Dmitry Reznikov, Evgenia Gavrilova, Ilya Tsimafeyeu
Publikováno v:
Journal of Clinical Oncology. 40:304-304
304 Background: FGFR2 promotes gastric cancer progression, suggesting that inhibition of FGFR2 may be an important therapeutic strategy. Alofanib (RPT835) is a small molecule, allosteric inhibitor that binds to the non-active extracellular site of II